Domenico Russo

Summary

Affiliation: University of Udine
Country: Italy

Publications

  1. ncbi Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation
    R Stocchi
    Department of Medical and Morphological Research, University Hospital, Udine, Italy
    Haematologica 84:71-9. 1999
  2. ncbi Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients
    Alessandra Sperotto
    Division of Haematology, Bone Marrow Transplant Unit, Department of Medical and Morphological Research, University Hospital, Udine, Italy
    Adv Clin Path 6:77-85. 2002
  3. ncbi P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia
    Daniela Damiani
    Division of Haematology, Department of Medical and Morphological Research, University Hospital, Udine, Italy
    Br J Haematol 116:519-27. 2002
  4. ncbi B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia
    Francesco Zaja
    Clinica Ematologica, Policlinico Universitario, Udine, Italy
    Haematologica 87:189-95. 2002
  5. ncbi Sea-blue histiocytosis secondary to Niemann-Pick disease type B: a case report
    A Candoni
    Department of Bone Marrow Transplantation, University Hospital, Udine, Italy
    Ann Hematol 80:620-2. 2001
  6. ncbi Hepatitis c and lymphoma
    F Silvestri
    Division of Hematology, University Hospital, 33100 Udine, Italy
    Curr Oncol Rep 2:172-5. 2000
  7. ncbi Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous stem cell transplantation
    F Patriarca
    Clinica Ematologica, Policlinico Universitario, P zale S Maria della Misericordia, 33100 Udine, Italy
    Haematologica 85:982-5. 2000
  8. ncbi High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome
    F Patriarca
    Clinica Ematologica, Policlinico Universitario, P zale S Maria della Misericordia, 33100 Udine, Italy
    Haematologica 85:269-74. 2000
  9. ncbi Castleman's disease: an unusual cause of mediastinal mass and anemia
    A Candoni
    Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy
    Clin Ter 153:217-9. 2002
  10. ncbi Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients
    Daniela Damiani
    Clinica Ematologica e Centro Trapianti e Terapie Cellulari C Melzi, Azienda Ospedaliero Universitaria di Udine, Dipartimento di Ricerche Mediche e Morfologiche, Universita di Udine, Udine, Italy
    Leuk Res 34:942-5. 2010

Detail Information

Publications32

  1. ncbi Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation
    R Stocchi
    Department of Medical and Morphological Research, University Hospital, Udine, Italy
    Haematologica 84:71-9. 1999
    ..The aim of this article is to describe the main strategies used to prevent HCMV infection and to improve the survival after CMV disease in bone marrow transplant recipients...
  2. ncbi Autologous stem cell transplantation for Hodgkin's lymphoma: results and prognostic factors in 51 high-risk patients
    Alessandra Sperotto
    Division of Haematology, Bone Marrow Transplant Unit, Department of Medical and Morphological Research, University Hospital, Udine, Italy
    Adv Clin Path 6:77-85. 2002
    ..0% of patients submitted to ASCT with refractory disease can be potentially rescued by transplant...
  3. ncbi P-glycoprotein, lung resistance-related protein and multidrug resistance-associated protein in de novo adult acute lymphoblastic leukaemia
    Daniela Damiani
    Division of Haematology, Department of Medical and Morphological Research, University Hospital, Udine, Italy
    Br J Haematol 116:519-27. 2002
    ..LRP and MRP overexpression seems to be a rare event and no conclusion can be drawn on its prognostic role...
  4. ncbi B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia
    Francesco Zaja
    Clinica Ematologica, Policlinico Universitario, Udine, Italy
    Haematologica 87:189-95. 2002
    ..This could interfere with the production of autoantibodies in some immune diseases. The objective of this study was to assess the effects of rituximab in autoimmune hemolytic anemia and thrombocytopenia...
  5. ncbi Sea-blue histiocytosis secondary to Niemann-Pick disease type B: a case report
    A Candoni
    Department of Bone Marrow Transplantation, University Hospital, Udine, Italy
    Ann Hematol 80:620-2. 2001
    ..This is a simple and noninvasive method that is useful whenever clinical and morphological finding are relevant, and a primary hematological disorder has been ruled out...
  6. ncbi Hepatitis c and lymphoma
    F Silvestri
    Division of Hematology, University Hospital, 33100 Udine, Italy
    Curr Oncol Rep 2:172-5. 2000
    ..Experimental data further support this hypothesis. Recent findings include demonstration that patients with hematologic malignancies can be treated safely with standard and high-dose chemotherapy even in the presence of HCV infection...
  7. ncbi Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous stem cell transplantation
    F Patriarca
    Clinica Ematologica, Policlinico Universitario, P zale S Maria della Misericordia, 33100 Udine, Italy
    Haematologica 85:982-5. 2000
    ..The occurrence of chronic lymphocyte leukemia (CLL) and multiple myeloma (MM) in a single individual is rare and there is no consensus about the clonal relationship of the two disorders and no clinical data about the response to therapy...
  8. ncbi High-dose therapy in multiple myeloma: effect of positive selection of CD34+ peripheral blood stem cells on hematologic engraftment and clinical outcome
    F Patriarca
    Clinica Ematologica, Policlinico Universitario, P zale S Maria della Misericordia, 33100 Udine, Italy
    Haematologica 85:269-74. 2000
    ..Positive selection of peripheral blood stem cells (PBSC) has been investigated in multiple myeloma (MM) with the aims of reducing plasma cell (PC) contamination of the leukaphereses and improving clinical outcome of autografted patients...
  9. ncbi Castleman's disease: an unusual cause of mediastinal mass and anemia
    A Candoni
    Division of Hematology and Bone Marrow Transplantation, University Hospital, Udine, Italy
    Clin Ter 153:217-9. 2002
    ..The optimal therapeutic approach is unknown but a complete surgical resection is treatment of choice for localized disease...
  10. ncbi Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients
    Daniela Damiani
    Clinica Ematologica e Centro Trapianti e Terapie Cellulari C Melzi, Azienda Ospedaliero Universitaria di Udine, Dipartimento di Ricerche Mediche e Morfologiche, Universita di Udine, Udine, Italy
    Leuk Res 34:942-5. 2010
    ..5% vs 28.5%) and earlier relapse occurred in BCRP+ patients. Also overall survival was affected by BCRP positivity, and survival significantly worsened in case of concomitant PGP and BCRP over-expression...
  11. doi Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse
    Mario Tiribelli
    Division of Hematology and Bone Marrow Transplantation, Department of Medical and Morphological Researches, AOU Udine, Udine, Italy
    Cancer 117:2156-62. 2011
    ....
  12. ncbi The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype
    Daniela Damiani
    Chair of Hematology and Division of Hematology and Bone Marrow Transplantation, Udine University, Udine, Italy
    Hematol Oncol 25:38-43. 2007
    ..This finding could be used to stratify patients with different prognosis and to design risk-adapted therapeutic strategies...
  13. ncbi Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells
    Angela Michelutti
    Division of Hematology, Department of Medical and Morphological Research, University Hospital, P le S Maria della Misericordia, 33100, Udine, Italy
    Cancer Chemother Pharmacol 57:517-24. 2006
    ..These patients may be candidates for alternative therapeutic strategies and the combination of DNX and Amifostine is an attractive treatment for these cases where a low nonhematological toxicity is required...
  14. doi Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years
    Anna Candoni
    Division of Hematology, Bone Marrow Transplantation Unit, Department of Clinical and Morphological Research, University Hospital, Udine, Italy
    Leuk Res 32:1800-8. 2008
    ..Nevertheless, the role and safety of this antibody target-therapy in first-line chemotherapy in patients younger than 65 years has not yet been defined...
  15. ncbi Disposition of liposomal daunorubicin during cotreatment with cytarabine in patients with leukaemia
    Federico Pea
    Department of Experimental and Clinical Pathology and Medicine, Institute of Clinical Pharmacology and Toxicology, University of Udine, Udine, Italy
    Clin Pharmacokinet 42:851-62. 2003
    ..To investigate the pharmacokinetics and pharmacodynamics of liposomal daunorubicin (DaunoXome) 80 or 100 mg/m(2) on days 1, 2 and 3 coadministered with standard or high-dose cytarabine to patients with poor-risk acute leukaemia...
  16. ncbi Rituximab for the treatment of type II mixed cryoglobulinemia
    Francesco Zaja
    Arthritis Rheum 46:2252-4; author reply 2254-5. 2002
  17. ncbi A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia
    Michele Baccarani
    L and A Seràgnoli Institute of Hematology and Medical Oncology, S Orsola Hospital, University of Bologna, Italy
    Blood 99:1527-35. 2002
    ....
  18. ncbi Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients
    Michele Malagola
    Chair of Haematology, Unit of Blood Diseases and Cell Therapies, University of Brescia, Brescia, Italy
    Br J Haematol 136:87-95. 2007
    ..In this setting of patients, large prospective randomised studies should be planned...
  19. ncbi The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients
    Pier Paolo Piccaluga
    Haematologica 89:1269-71. 2004
    ..000). Moreover, the 6 patients with a bcr-abl/GAPDHx100,000 ratio <2 after 4 weeks of treatment had significantly better RFS (10.5 vs 4 months) (p=0.004)...
  20. ncbi Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients
    Domenico Russo
    Unit of Blood Diseases and Cell Therapy, Brescia University, Brescia, Italy
    Br J Haematol 131:172-9. 2005
    ..Our prospective randomised study confirmed the anti-leukaemic effect and the low toxic profile of FLAI as induction treatment for newly diagnosed AML patients...
  21. ncbi Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
    Michele Malagola
    Blood 105:904; author reply 905. 2005
  22. ncbi Kaposi's sarcoma occurring in a young black man after kidney transplantation
    Antonietta De Blasio
    Department of Nephrology, School of Medicine, University Frederico, Naples, Italy
    Nephrol Dial Transplant 20:2839-41. 2005
  23. ncbi Interferon-alfa for chronic myeloid leukemia
    Michele Baccarani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna and S Orsola Hospital, Bologna, Italy
    Semin Hematol 40:22-33. 2003
    ....
  24. ncbi Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
    Hagop Kantarjian
    M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 346:645-52. 2002
    ..Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase...
  25. doi Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases
    Michele Malagola
    Unit of Blood Diseases and Cell Therapies, University of Brescia, Brescia, Italy
    Eur J Haematol 81:354-63. 2008
    ..The intensification of induction chemotherapy and the use of non-conventional drugs such as fludarabine are considered responsible for the increased risk of infections...
  26. ncbi Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients
    Carlo Gambacorti-Passerini
    Department of Experimental Oncology, Istituto Nazionale Tumori, Milano, Italy
    Clin Cancer Res 9:625-32. 2003
    ..alpha1 acid glycoprotein (AGP) binds to imatinib with high affinity and inhibits imatinib activity in vitro and in vivo in an animal model. A pharmacokinetics analysis of imatinib was undertaken in CML patients...
  27. doi Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia
    Aldo M Roccaro
    Bing Center for Waldenstrom s Macroglobulinemia, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:1849-58. 2008
    ..Whether resveratrol could inhibit proliferation or induce cytotoxicity in Waldenström's macroglobulinemia (WM) was investigated...
  28. ncbi Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 92:1721-2. 2007
    ..No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild...
  29. ncbi Ramipril in post-renal transplant erythrocytosis
    Raffaela Esposito
    Department of Nephrology, School of Medicine, University of Naples Federico II, Naples Italy
    J Nephrol 20:57-62. 2007
    ..In this study the dose-response of a single ACEI was assessed, and patients were followed up for 1 year. The role of ACE gene polymorphism in both prevalence of PTE and successful response to ACEI therapy was also tested...
  30. ncbi Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia
    Michele Baccarani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Via Massarenti, 9 40138 Bologna, Italy
    Blood 104:4245-51. 2004
    ..The BCR/ABL transcript was reduced by at least 3 logs in 68% of complete cytogenetic responders. These data of toxicity, compliance, and efficacy may assist in the design and preparation of prospective studies...
  31. ncbi Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres
    Livio Pagano
    Institute of Hematology, Sacred Heart Catholic University, Largo Francesco Vito 1, I 00168 Rome, Italy
    Br J Haematol 117:379-86. 2002
    ..Multivariate analysis showed that prolonged steroid treatment (P < 0.006) and a radiological picture of diffuse lung involvement (P < 0.003) were negative diagnostic factors...
  32. ncbi Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 24:454-9. 2006
    ..Imatinib mesylate is a potent inhibitor of BCR-ABL, the constitutively active tyrosine kinase protein critical for the pathogenesis of chronic myeloid leukemia...